Electrospun wound dressing as a promising tool for the therapeutic delivery of ascorbic acid and caffeine
Aim: The aim of this work is to formulate a wound dressing for the delivery of ascorbic acid and caffeine. Method: A wound dressing was developed from electrospun nanofiber containing ascorbic acid and caffeine. In vitro drug release was performed at 25°C and 32°C. Wound healing activity of the nanofiber mats was tested in vivo using rat model with skin excision. Antifungal activity of the dressing was tested on Candida albicans using the disc diffusion method. Results & conclusion: Zone of inhibition was 6.7 mm for caffeine dressing; however, inhibition zone increased to 16.7 mm for samples containing both caffeine and ascorbic acid. Animals treated with ascorbic acid showed collagen deposition and very few fibroblast cells. Blood vessels and fibroblasts were increased in caffeine-loaded dressings compared with the ascorbic acid group. The findings of the present work suggest the benefits of topical ascorbic acid and caffeine for its high wound healing effects.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Therapeutic delivery - 10(2019), 12 vom: 16. Dez., Seite 757-767 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Avizheh, Laya [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3G6A5W338E |
|---|
| Anmerkungen: |
Date Completed 29.04.2020 Date Revised 29.04.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/tde-2019-0059 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM304416177 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM304416177 | ||
| 003 | DE-627 | ||
| 005 | 20231225114934.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/tde-2019-0059 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1014.xml |
| 035 | |a (DE-627)NLM304416177 | ||
| 035 | |a (NLM)31840563 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Avizheh, Laya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Electrospun wound dressing as a promising tool for the therapeutic delivery of ascorbic acid and caffeine |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.04.2020 | ||
| 500 | |a Date Revised 29.04.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: The aim of this work is to formulate a wound dressing for the delivery of ascorbic acid and caffeine. Method: A wound dressing was developed from electrospun nanofiber containing ascorbic acid and caffeine. In vitro drug release was performed at 25°C and 32°C. Wound healing activity of the nanofiber mats was tested in vivo using rat model with skin excision. Antifungal activity of the dressing was tested on Candida albicans using the disc diffusion method. Results & conclusion: Zone of inhibition was 6.7 mm for caffeine dressing; however, inhibition zone increased to 16.7 mm for samples containing both caffeine and ascorbic acid. Animals treated with ascorbic acid showed collagen deposition and very few fibroblast cells. Blood vessels and fibroblasts were increased in caffeine-loaded dressings compared with the ascorbic acid group. The findings of the present work suggest the benefits of topical ascorbic acid and caffeine for its high wound healing effects | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a ascorbic acid | |
| 650 | 4 | |a caffeine | |
| 650 | 4 | |a electrospinning | |
| 650 | 4 | |a nanofiber | |
| 650 | 4 | |a topical drug delivery | |
| 650 | 4 | |a wound healing | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 650 | 7 | |a Caffeine |2 NLM | |
| 650 | 7 | |a 3G6A5W338E |2 NLM | |
| 650 | 7 | |a Ascorbic Acid |2 NLM | |
| 650 | 7 | |a PQ6CK8PD0R |2 NLM | |
| 700 | 1 | |a Peirouvi, Tahmineh |e verfasserin |4 aut | |
| 700 | 1 | |a Diba, Kambiz |e verfasserin |4 aut | |
| 700 | 1 | |a Fathi-Azarbayjani, Anahita |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic delivery |d 2010 |g 10(2019), 12 vom: 16. Dez., Seite 757-767 |w (DE-627)NLM203937082 |x 2041-6008 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2019 |g number:12 |g day:16 |g month:12 |g pages:757-767 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/tde-2019-0059 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2019 |e 12 |b 16 |c 12 |h 757-767 | ||